補(bǔ)體成分5a(C5a)等多因子檢測試劑盒(流式熒光法)
Multiplex Assay Kit for Complement Component 5a (C5a) ,etc. by CBA (Cytometric Bead Array)
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測補(bǔ)體成分5a(C5a)等多因子檢測試劑盒(流式熒光法)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的補(bǔ)體成分5a(C5a)等多因子檢測試劑盒(流式熒光法)（加標(biāo)樣品），重復(fù)測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 80-97 | 83 |
| EDTA plasma(n=5) | 85-99 | 93 |
| heparin plasma(n=5) | 96-104 | 101 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定，每個樣本使用同一試劑盒重復(fù)測定8次，分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的補(bǔ)體成分5a(C5a)等多因子檢測試劑盒(流式熒光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中補(bǔ)體成分5a(C5a)等多因子檢測試劑盒(流式熒光法)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 93-105% | 97-104% | 88-104% | 85-105% |
| EDTA plasma(n=5) | 93-101% | 88-97% | 94-101% | 79-101% |
| heparin plasma(n=5) | 79-88% | 79-93% | 78-91% | 99-105% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實驗室的環(huán)境條件需盡量保持一致，尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進(jìn)行操作可減少人為誤差。
實驗流程
1、向?qū)嶒灠迕靠變?nèi)加入200μL分析緩沖液以預(yù)濕；
2、實驗前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
3、加樣（標(biāo)準(zhǔn)品、樣本、磁珠），標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL，25°C酶標(biāo)板振蕩器孵育2小時；
4、磁吸甩干，加檢測溶液A 100μL，25°C酶標(biāo)板振蕩器孵育1小時；
5、磁吸甩干，加檢測溶液B 100μL，25°C振動孵育30分鐘；
6、磁吸洗板1次；
7、加鞘液100μL，旋渦震蕩10分鐘后讀數(shù)。
實驗原理
將補(bǔ)體成分5a(C5a)等多因子檢測試劑盒(流式熒光法)抗體包被于磁性微球表面，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠，其中的補(bǔ)體成分5a(C5a)等多因子檢測試劑盒(流式熒光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的補(bǔ)體成分5a(C5a)等多因子檢測試劑盒(流式熒光法)抗體，加入PE標(biāo)記的親和素，用流式細(xì)胞儀讀數(shù)。MFI值和樣品中的補(bǔ)體成分5a(C5a)等多因子檢測試劑盒(流式熒光法)濃度呈正相關(guān)。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Oryctolagus cuniculus (Rabbit，兔) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA388Rb02 | 補(bǔ)體成分5a(C5a)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA388Rb03 | 補(bǔ)體成分5a(C5a)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA388Rb01 | 補(bǔ)體成分5a(C5a)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| SEA388Rb | 補(bǔ)體成分5a(C5a)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA388Rb | 補(bǔ)體成分5a(C5a)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| CMA388Rb | 補(bǔ)體成分5a(C5a)等多因子檢測試劑盒(流式熒光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Molecular Immunology | Cathepsin D is released after severe tissue trauma in vivo and is capable of generating C5a in vitro[ScienceDirect: S0161589011008297] |
| Journal of Reproductive Immunology | Elevated complement factor C5a in maternal and umbilical cord plasma in preeclampsia[PubMed: 23415845] |
| The Journal of Clinical Investigation | Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis[PubMed: PMC3195471] |
| Journal of Antimicrobial Chemotherapy | Efficacy of a synthetic antimicrobial peptidomimetic versus vancomycin in a Staphylococcus epidermidis device-related murine peritonitis model[Pubmed: 23645587] |
| Journal of Orthopaedic Research | Conversion from external fixator to intramedullary nail causes a second hit and impairs fracture healing in a severe trauma model[Pubmed: 23070742] |
| SpringerPlus | Therapeutic effects of sesame oil on monosodium urate crystal-induced acute inflammatory response in rats[Pubmed: 24353977] |
| American Journal fo Reproductive Immunology | Evaluation of the Markers of Inflammation in the Umbilical Cord Blood of Newborns of Mothers with Thrombophilia[Pubmed:25209155] |
| Gynecol Obstet Invest | Complement Split Products C3a/C5a and Receptors: Are They Regulated by Circulating Angiotensin II Type 1 Receptor Autoantibody in Severe Preeclampsia?[PubMed: 26485247] |
| Journal of Neuroimmunology | Acute and prolonged complement activation in the central nervous system during herpes simplex encephalitis[Pubmed:27235358] |
| International Immunopharmacology | Consistency and pathophysiological characterization of a rat polymicrobial sepsis model via the improved cecal ligation and puncture surgery[Pubmed:26802602] |
| Digital Repository | Dosagem de fra??es ativadas do sistema complemento em empiema induzido em ratos[10183] |
| Environmental Pollution | Cadmium-induced immune abnormality is a key pathogenic event in human and rat models of preeclampsia[pubmed:27511439] |
| Cancer Letters | Complement C5a/C5aR pathway potentiates the pathogenesis Q5 of gastric cancer by down-regulating p21 expression[pubmed:29031586] |
| Acta Paediatrica | Serum complement factor 5a levels are associated with nonalcoholic fatty liver disease in obese children[DOI:?10.1111/apa.14106] |
| Scientific Reports | Splenectomy modulates early immuno-inflammatory responses to trauma-hemorrhage and protects mice against secondary sepsis[Pubmed: 30291296] |
| Nutrients | The Beneficial Effects of Lactobacillus plantarum PS128 on High-Intensity, Exercise-Induced Oxidative Stress, Inflammation, and Performance in Triathletes[Pubmed: 30736479] |
| Journal of?NeuroVirology | Intrathecal complement activation by the classical pathway in tick-borne encephalitis[Pubmed: 30850976] |
| PLoS One | Sepsis causes right ventricular myocardial inflammation independent of pulmonary hypertension in a porcine sepsis model[Pubmed: 31247004] |
| Frontiers in Immunology | C5a/C5aR Pathway is Critical for the Pathogenesis of Psoriasis[Pubmed: 31447855] |
| Phytomedicine | Novel evidence that an alternative complement cascade pathway is involved in optimal mobilization of hematopoietic stem/progenitor cells in Nlrp3?…[] |
| Aging | C5aR deficiency attenuates the breast cancer development via the p38/p21 axis[Pubmed: 32669478] |
| STEM CELL REVIEWS AND REPORTS | A Novel Evidence That Mannan Binding Lectin (MBL) Pathway of Complement Cascade Activation is Involved in Homing and Engraftment of Hematopoietic Stem …[Pubmed: 32406006] |
| Modulation of C5a-C5aR interactions against murine mammary cancer cell line[] | |
| FASEB J | C‐reactive protein inhibits C3a/C3aR‐dependent podocyte autophagy in favor of diabetic kidney disease[Pubmed:35503088] |